You can’t reverse macular degeneration, but you can slow it down significantly and, in some cases, stop further vision loss. The outcome depends on which type you have, how early it’s caught, and what steps you take. For wet AMD, injections can stabilize or even improve vision in up to 90% of patients. For dry AMD, the options are more limited but growing, and lifestyle changes play a measurable role in both types.
Dry vs. Wet: Two Different Challenges
Most people with age-related macular degeneration (AMD) have the dry form, where the macula gradually thins with age. It progresses slowly, sometimes over years or decades, and there’s no single treatment that halts it completely. The wet form is less common but more urgent: abnormal blood vessels grow behind the retina and leak fluid, damaging the macula quickly. Any stage of dry AMD can convert to wet AMD at any point, which is why monitoring matters even when the disease feels stable.
In late-stage AMD of either type, straight lines may start to look wavy or crooked. A blurry spot can develop near the center of your vision and grow over time. Colors may look duller, and low-light vision gets noticeably worse.
Treating Wet AMD With Injections
Wet AMD has the most effective treatments available right now. Eye injections that block the growth signal for abnormal blood vessels have transformed outcomes over the past two decades. In major clinical trials, about 90 to 96% of patients who received monthly injections maintained their vision over one to two years, compared with roughly 53 to 64% of untreated patients. Beyond just holding steady, about one in three treated patients actually gained meaningful vision back.
Treatment typically starts with a series of monthly injections, then shifts to an as-needed schedule based on how your eye responds. In one study using this approach, patients gained an average of 11 letters on the eye chart over two years with roughly 10 total injections. The injections sound intimidating, but the eye is numbed first, and most people describe brief pressure rather than pain. The key is consistency: skipping or delaying appointments gives those abnormal vessels a chance to leak again.
New Treatments for Advanced Dry AMD
Until recently, there was nothing approved for geographic atrophy, the advanced form of dry AMD where patches of retinal cells die off permanently. That changed in 2023, when the FDA approved two injectable treatments that target the complement system, a part of the immune response that drives cell death in the retina. These drugs don’t restore lost vision, but they slow the rate at which the atrophy spreads.
There’s an important trade-off to be aware of. One of these treatments carries a 7 to 12% risk of triggering the wet form of AMD, depending on how frequently it’s given. That conversion can be treated with the standard injections described above, but it means patients on these therapies need close monitoring. Your retina specialist would weigh this risk against the speed of your geographic atrophy progression.
How the AREDS2 Formula Helps
For people with intermediate dry AMD or late AMD in one eye, a specific supplement formula tested in a large National Eye Institute trial can reduce the risk of progressing to advanced disease. The formula, known as AREDS2, contains:
- Vitamin C: 500 mg
- Vitamin E: 400 IU
- Zinc: 80 mg
- Lutein: 10 mg
- Zeaxanthin: 2 mg
These aren’t random multivitamins. The dosages were chosen based on clinical trial results, and the lutein and zeaxanthin replaced an earlier beta-carotene formula that raised lung cancer risk in smokers. Over-the-counter AREDS2 supplements are widely available and labeled as such. They’re most beneficial for people who already have intermediate or advanced AMD; if you only have early-stage changes, the evidence of benefit is less clear.
Diet Makes a Measurable Difference
A Mediterranean-style eating pattern, heavy on fruits, vegetables, fish, olive oil, and light on red meat, has one of the strongest dietary associations with slower AMD progression. In one study, people with high adherence to this diet were 2.2 times more likely to see their AMD progression slow compared to those with low adherence. Pooled data from two large European studies found that strong Mediterranean diet adherence was linked to a 41% lower risk of developing advanced AMD, with a particularly strong protective effect against geographic atrophy.
The likely reason is that this eating pattern delivers high levels of lutein, zeaxanthin, vitamin C, and omega-3 fatty acids, all of which help protect the retina from oxidative damage and inflammation. It’s also a low-glycemic diet, which matters because high blood sugar spikes appear to stress retinal cells over time. You don’t need to move to Greece. The core principle is eating more plants, more fish, using olive oil as your main cooking fat, and cutting back on processed food and red meat.
Smoking and AMD Risk
Smoking is the single largest modifiable risk factor for macular degeneration. Quitting helps, but the timeline for risk reduction is longer than most people expect. The elevated risk of developing wet AMD persists for up to 20 years after quitting. Women who smoked 25 or more cigarettes a day still had double the AMD risk 15 years after stopping. The encouraging finding is that after 20 years of not smoking, your risk drops back to the same level as someone who never smoked.
If you currently smoke and have early AMD, quitting now is the single most impactful thing you can do. The retina is one of the most metabolically active tissues in the body, and the toxic compounds in cigarette smoke damage it through both direct oxidative stress and reduced blood flow.
Monitoring at Home
An Amsler grid is a simple printed square of evenly spaced lines with a dot in the center. You should use one daily if you’ve been diagnosed with any stage of AMD. Hold it at normal reading distance, cover one eye, and focus on the center dot. Look for lines that appear wavy, blurred, or missing. If any of those changes are new, contact your retina doctor the same day. The shift from dry to wet AMD can happen suddenly, and catching it within days rather than weeks makes a real difference in how much vision can be saved.
Gene Therapy on the Horizon
The biggest limitation of current wet AMD treatment is the need for repeated injections, sometimes for years. Gene therapy aims to solve this by reprogramming cells in the eye to produce their own anti-growth-factor proteins continuously after a single procedure. Three leading candidates are currently in phase 3 clinical trials involving hundreds of patients, with results expected in the coming years. One CRISPR-based therapy has also entered early human testing. These aren’t available yet outside of clinical trials, but they represent the most realistic path to a one-time treatment for wet AMD.